Kura Oncology (NASDAQ:KURA) CEO Troy Edward Wilson Purchases 100,000 Shares of Stock

Kura Oncology, Inc. (NASDAQ:KURA) CEO Troy Edward Wilson bought 100,000 shares of the firm’s stock in a transaction dated Monday, August 24th. The shares were acquired at an average cost of $12.39 per share, with a total value of $1,239,000.00. Following the completion of the transaction, the chief executive officer owned 479,194 shares in the company, valued at approximately $5,937,213.66. The trade was a 26.37% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Troy Edward Wilson also recently made the following trade(s):

• On Monday, August 17th, Troy Edward Wilson purchased 100,000 shares of Kura Oncology stock. The stock was bought at an average cost of $11.12 per share, for a total transaction of $1,112,000.00.

Kura Oncology Stock Performance

KURA traded up $0.51 during trading on Monday, hitting $12.40. 2,673,296 shares of the company traded hands, compared to its average volume of 1,620,411. Kura Oncology, Inc. has a one year low of $7.36 and a one year high of $12.90. The stock’s fifty day moving average is $10.53 and its 200 day moving average is $9.47. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The firm has a market cap of $1.10 billion, a P/E ratio of -3.68 and a beta of 0.38.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The firm had revenue of $20.87 million for the quarter, compared to analysts’ expectations of $20.16 million. As a group, equities analysts predict that Kura Oncology, Inc. will post -3.23 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

KURA has been the subject of several research reports. Wall Street Zen raised Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Raymond James Financial set a $24.00 price target on Kura Oncology in a research report on Monday. Citizens Jmp reissued a “market outperform” rating and issued a $24.00 price objective on shares of Kura Oncology in a report on Monday. Jefferies Financial Group set a $24.00 price objective on Kura Oncology in a research note on Thursday, May 28th. Finally, Wedbush upped their price objective on shares of Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday, August 13th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $25.40.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds have recently made changes to their positions in KURA. Dimensional Fund Advisors LP increased its position in shares of Kura Oncology by 32.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock worth $11,591,000 after purchasing an additional 348,127 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in Kura Oncology by 69.7% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 568,845 shares of the company’s stock worth $6,240,000 after buying an additional 233,633 shares in the last quarter. UBS Group AG grew its stake in Kura Oncology by 118.3% in the 4th quarter. UBS Group AG now owns 1,060,025 shares of the company’s stock worth $11,014,000 after buying an additional 574,455 shares in the last quarter. Nan Fung Trinity HK Ltd. increased its holdings in shares of Kura Oncology by 317.9% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 964,880 shares of the company’s stock worth $10,025,000 after buying an additional 734,000 shares during the last quarter. Finally, Janney Montgomery Scott LLC raised its position in shares of Kura Oncology by 285.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 158,850 shares of the company’s stock valued at $1,291,000 after buying an additional 117,650 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.